The implementation of molecular diagnostic (MDx) technologies has played a pivotal role throughout the coronavirus crisis. Real‑time PCR (qPCR)‑based laboratory-developed tests and in vitro diagnostic tests that detect viral nucleic acids have enabled widespread screening efforts, as well as rapid diagnosis of infected individuals.
As the demand for coronavirus testing declines, an opportunity arises to expand MDx test menus to include a variety of other targets, as outlined in this new infographic. These include respiratory, urinary, vaginal, sexually transmitted, and gastrointestinal pathogens, as well as antibiotic resistance markers.
|
